Abstract

AbstractPurposeGlaucoma refers to a group of diseases characterised by visual field damage and optic neuropathy. In glaucoma, retinal ganglion cell (RGC) death halts the progression of visual information from the eye to the brain, causing permanent visual loss. Due to their crucial role in the pathophysiology of glaucomatous injury, strategies delaying or preventing RGC death are being increasingly recognised as important to incorporate into novel approaches to glaucoma. However, the successful development of such therapies is reliant upon a comprehensive understanding of the mechanisms underlying RGC dysfunction. This study aims to help elucidate this by examining the difference between RGC layer nuclei counts, inner plexiform layer (IPL) thickness, and TrkB signalling in the retina between control and glaucoma human samples.MethodsNine healthy and eight glaucomatous retinas were obtained from the Mayo Clinic, US. 2‐3mm explants from peripheral and central regions were probed for p‐TrkB via immunohistochemistry. Six images per retinal section were quantified for TrkB signalling using ImageJ. RGC layer nuclei counts and IPL thickness measurements were taken as evidence of glaucomatous damage.ResultsThere was a loss of nuclei in the RGC layer, a decrease in IPL thickness, and loss of p‐TrkB signalling in the peripheral human glaucoma samples compared to controls. These changes correlated with a loss of visual field information. No significant changes were observed in the central retina.ConclusionsOur findings support the observation that patients lose peripheral vision early in glaucoma. This convincingly supports a picture of RGC death disrupting the transmission of visual information from the peripheral retina in glaucoma patients. Reduced TrkB signalling in glaucoma also demonstrates the importance of this signalling pathway in maintaining RGC survival. Investigating ways to restore, or preserve, TrkB phosphorylation may be beneficial in the treatment of glaucoma.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.